Ripretinib

Drug Overview

Ripretinib is an oral, broad-spectrum kinase inhibitor designed as a switch-control tyrosine kinase inhibitor (TKI). It is specifically engineered to target a wide range of KIT and PDGFRA mutations, including those that cause resistance to other therapies, in advanced gastrointestinal stromal tumors (GIST).

• Generic Name: Ripretinib
• US Brand Name: Qinlock®
• Drug Class: Kinase Inhibitor (Switch-Control TKI)
• Route of Administration: Oral (tablet)
• FDA Approval Status: Approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

What Is It and How Does It Work? (Mechanism of Action):

Ripretinib is a targeted therapy with a unique dual mechanism designed to inhibit KIT and PDGFRA signaling broadly, overcoming common resistance mutations that develop in GIST.

• Molecular Target: Ripretinib binds to the switch pocket of the kinase domain of KIT and PDGFRA. These receptors are often constitutively activated by mutations in GIST, driving tumor growth.
• Cellular Impact: It functions via two complementary actions: 1) Inhibition of the Active Kinase Conformation: Binds to and blocks the ATP-binding site of the activated kinase. 2) Locking the Kinase in an Inactive Conformation: Its unique structure allows it to also bind to the activation loop (“switch pocket”), preventing the kinase from adopting its active shape. This dual-binding inhibits both monomeric and dimeric forms of the kinase.
• Result: This “switch-control” inhibition potently blocks downstream signaling through the MAPK and PI3K pathways, which are critical for cell proliferation and survival. By targeting a broad spectrum of primary and secondary resistance mutations (including those in the activation loop), ripretinib effectively suppresses tumor growth in heavily pre-treated GIST.
• Targeted Therapy Characteristic: As a switch-control TKI, ripretinib is a “smart drug” or targeted therapy designed with structural precision to overcome the specific molecular mechanisms of resistance that evolve in GIST.

FDA Approved Clinical Indications:

Oncological Uses:

• Gastrointestinal Stromal Tumor (GIST): Treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.

Non-Oncological Uses:

• There are currently no FDA-approved non-oncological indications for ripretinib.

Dosage and Administration Protocols:

Ripretinib is taken orally once daily. Consistent administration is vital to maintain therapeutic drug concentrations and suppress tumor growth.

Renal and Hepatic Dose Adjustments

• Renal Impairment: No initial dose adjustment is required for patients with mild to severe renal impairment.
• Hepatic Impairment: Dose reduction is necessary for patients with moderate hepatic impairment (Child-Pugh Class B). The recommended initial dose should be reduced to 100 mg QD. Use in severe hepatic impairment (Child-Pugh Class C) is not recommended due to limited data.
• Drug Interactions: Strong CYP3A4 inducers (e.g., Rifampin) can significantly decrease Ripretinib exposure; concurrent use should be avoided, or the Ripretinib dose increased with caution.

Clinical Efficacy and Research Results:

The approval of ripretinib was based on the pivotal phase III INVICTUS trial in fourth-line and later GIST. Data from this and subsequent studies (2020-2025) define its role.

• Progression-Free Survival (PFS): In the INVICTUS trial, ripretinib significantly improved median PFS to 6.3 months compared to 1.0 month for placebo in heavily pretreated patients, reducing the risk of progression or death by 85%.
• Overall Survival (OS): Ripretinib demonstrated a significant improvement in median OS at 15.1 months vs. 6.6 months for placebo.
• Objective Response Rate (ORR): The confirmed ORR was 9.4% vs. 0% for placebo, with an additional 62% achieving stable disease, indicating potent disease control.
• Contemporary Context: Ripretinib is the standard of care in the fourth-line setting. Ongoing research (INTRIGUE trial) is evaluating its efficacy versus sunitinib in the second-line setting, showing non-inferiority in patients with KIT exon 11 mutations.

Safety Profile and Side Effects:

Black Box Warning:

• None for ripretinib.

Common Side Effects (>20%):

• Dermatological: Alopecia (hair loss), fatigue, nausea, abdominal pain, constipation, myalgia (muscle pain), diarrhea.
• Specific Key Toxicity: Palmar-plantar erythrodysesthesia (hand-foot syndrome).
• Other: Hypertension, vomiting.

Management Strategies:

• Hand-Foot Syndrome (HFS): Proactive skin care with moisturizers, urea-based creams, and wearing comfortable shoes. Dose interruption followed by dose reduction is effective for Grade 2+ HFS.
• Hypertension: Monitor blood pressure regularly after initiation. Initiate or adjust antihypertensive therapy as needed. Dose interruption may be required for severe hypertension.
• Alopecia: Typically manageable with supportive counseling.
• Gastrointestinal Symptoms: Manage with standard antiemetics and antidiarrheals.

Serious Adverse Events

• New Primary Cutaneous Malignancies: Increased risk of cutaneous squamous cell carcinoma (cuSCC) and basal cell carcinoma. Dermatologic evaluation is recommended prior to initiation and routinely during treatment.
• Hypertensive Crisis.
• Cardiac Dysfunction (decreased ejection fraction).
• Embryo-Fetal Toxicity.

Research Areas:

Ripretinib is a focus of active clinical research (2020-2025) to expand its utility in GIST and explore its potential in other cancers driven by KIT/PDGFRA. Key areas include:

1. Earlier Lines of Therapy: The INTRIGUE trial established its role in second-line therapy. Further studies are exploring its use in the adjuvant (post-surgery) setting.
2. Combination Strategies: Investigating ripretinib in combination with other targeted agents, chemotherapy, and immunotherapy to overcome resistance and improve depth of response.
3. Other Tumor Types: Evaluating its activity in other KIT/PDGFRA-mutant cancers, such as systemic mastocytosis and melanoma.

Patient Management & Practical Recommendations:

Pre-treatment Tests:

• Molecular Testing: Confirm diagnosis of GIST and review mutational status (KIT/PDGFRA) if available.
• Blood Pressure Measurement: Baseline and control of pre-existing hypertension.
• Dermatologic Exam: Baseline skin evaluation.
• Cardiac Evaluation: Baseline assessment of left ventricular ejection fraction (LVEF) via echocardiogram or MUGA scan.
• Comprehensive Metabolic Panel and CBC.
• Pregnancy Test for women of childbearing potential.

Precautions During Treatment:

• Blood Pressure Monitoring: Monitor at least weekly for the first month, then at least monthly.
• Skin Surveillance: Perform regular skin self-exams. Schedule periodic dermatologic evaluations.
• Cardiac Monitoring: Monitor for signs/symptoms of heart failure; assess LVEF as clinically indicated.
• Fertility Counseling: Discuss potential impact on fertility prior to treatment.

Do’s and Don’ts:

• DO take your medication once daily with or without food at the same time each day.
• DO monitor your blood pressure as instructed and report significant elevations.
• DO perform regular skin checks and report any new or changing skin lesions immediately.
• DO use moisturizers proactively on hands and feet to help prevent hand-foot syndrome.
• DON’T become pregnant or father a child while on this medication and for at least 1 week after the last dose.
• DON’T start any new medications, especially antihypertensives or other drugs that may affect heart function, without consulting your oncology team.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved use and key risks of ripretinib and is not a substitute for professional medical advice. Treatment decisions are highly individualized. Always consult your qualified healthcare provider for advice on your specific condition and treatment.